New York, Feb 11, 2026, 14:42 (EST) — Regular session
Elevance Health shares climbed 1.5% to $330.68 by early Wednesday afternoon, recovering from an intraday dip to $322.01 as investors grappled with new political pressure on the Affordable Care Act market. Trading volume hovered around 670,000 shares.
The reason this matters now is straightforward: ACA exchanges lie right where policy meets claims costs, and insurers are already working to finalize enrollment and pricing assumptions for 2026. Any fresh compliance requirements or changes in who signs up can quickly impact profit margins.
The move coincided with a slight boost in the sector. The Health Care Select Sector SPDR fund rose roughly 0.5%, the S&P 500 ETF nudged higher, and the Dow ETF showed little movement.
House Judiciary Committee Chair Jim Jordan served subpoenas on Elevance and seven other insurers Monday, Axios reported, demanding records on premium subsidies and possible fraud linked to those subsidies. The documents requested include counts of subsidized enrollees, funds received, plus related communications and audits. These subsidies, called advance premium tax credits, are federal payments sent to insurers to reduce monthly premiums for customers. An AHIP spokesperson told Axios that health plans back “strong program integrity measures.” Axios
The committee pointed to a Government Accountability Office review revealing billions in unreconciled Obamacare subsidies annually, according to Reuters. CVS confirmed it received the letter and is cooperating, Centene said it’s supplying information, and Blue Shield of California insisted its data shows no sign of “phantom enrollees,” the report noted. Reuters
Most managed-care stocks climbed: UnitedHealth jumped 2.2%, Cigna picked up 1.7%, Centene increased by 2.1%, and CVS edged up 0.8%. Humana, however, dropped roughly 1.9%.
Since late January, Elevance has been reshaping the narrative after reporting fourth-quarter operating revenue of $49.3 billion. The company projected adjusted diluted EPS for 2026 at “at least $25.50.” CEO Gail Boudreaux expressed confidence that adjusted EPS growth will rebound to at least 12% in 2027. Elevancehealth
Analysts are sounding more cautious. Morningstar’s Julie Utterbeck described the earlier rebound as “a relief rally from the big sell-off,” and Leerink’s Whit Mayo noted, “Guidance reflects continued pressure in Medicaid.” Reuters
RBC Capital Markets downgraded Elevance to Sector Perform from Outperform earlier this month, citing a weaker 2026 outlook and reduced margin targets that bring the stock closer to fair value. The firm also cut its price target from $392 to $358.
A recent annual report highlighted just how dependent major insurers are on government programs: Elevance’s 2025 10-K revealed that roughly 32% of its consolidated revenue is tied to U.S. government agencies.
The policy battle tends to escalate quickly. Stricter verification measures or a broader probe into broker actions and enrollments might drive up administrative expenses or shrink membership, especially as claim costs remain a concern. Investors keep a close eye on the medical loss ratio — the portion of premiums used for medical care — since a rising ratio cuts into profits.
February 23 is the key date for insurers to respond to subpoenas, according to Healthcare Dive. Traders will be alert for hints that the investigation might broaden, and if Washington’s next steps will shift the dynamics around ACA enrollment and pricing as the new cycle approaches.
